Compare Stocks: MPH, HEXO, VM, and VIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEXO HEXO		C$0.00	C$0.85 ▼ C$4.97	C$38.72M	2.13	253,024 shs	72,643 shs
MPH Medicure	C$1.36	C$1.17	C$0.85 ▼ C$1.43	C$14.19M	0.442695	3,030 shs	1,300 shs
VIR Vir Biotechnology	$9.18 +1.9%	$9.29	$4.25 ▼ $11.66	$1.55B	1.66	2.49 million shs	516,788 shs
VM Voyageur Pharmaceuticals	C$0.17 -2.9%	C$0.13	C$0.07 ▼ C$0.20	C$37.35M	0.619058	118,371 shs	102,810 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEXO HEXO	0.00%	0.00%	0.00%	0.00%	0.00%
MPH Medicure	0.00%	+4.62%	+27.10%	+14.29%	+18.26%
VIR Vir Biotechnology	+0.45%	+2.62%	-5.16%	+2.39%	+96.94%
VM Voyageur Pharmaceuticals	+3.03%	+13.33%	+21.43%	+70.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEXO HEXO		C$0.00	C$0.85 ▼ C$4.97	C$38.72M	2.13	253,024 shs	72,643 shs
MPH Medicure	C$1.36	C$1.17	C$0.85 ▼ C$1.43	C$14.19M	0.442695	3,030 shs	1,300 shs
VIR Vir Biotechnology	$9.18 +1.9%	$9.29	$4.25 ▼ $11.66	$1.55B	1.66	2.49 million shs	516,788 shs
VM Voyageur Pharmaceuticals	C$0.17 -2.9%	C$0.13	C$0.07 ▼ C$0.20	C$37.35M	0.619058	118,371 shs	102,810 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEXO HEXO	0.00%	0.00%	0.00%	0.00%	0.00%
MPH Medicure	0.00%	+4.62%	+27.10%	+14.29%	+18.26%
VIR Vir Biotechnology	+0.45%	+2.62%	-5.16%	+2.39%	+96.94%
VM Voyageur Pharmaceuticals	+3.03%	+13.33%	+21.43%	+70.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEXO HEXO	0.00	N/A	N/A	N/A
MPH Medicure	0.00	N/A	N/A	N/A
VIR Vir Biotechnology	2.89	Moderate Buy	$20.63	124.80% Upside
VM Voyageur Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MPH, HEXO, VM, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	VIR Vir Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
7/8/2026	VIR Vir Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	VIR Vir Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$23.00 ➝ $27.00
6/3/2026	VIR Vir Biotechnology	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$20.00 ➝ $21.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEXO HEXO	C$124.10M	0.00	N/A	1.55	C$3.24 per share	0.00
MPH Medicure	C$31.32M	0.45	C$0.55 per share	2.49	C$1.21 per share	1.12
VIR Vir Biotechnology	$68.56M	22.65	N/A	N/A	$5.81 per share	1.58
VM Voyageur Pharmaceuticals	C$47.24K	790.58	C$0.00 per share	35.00	C$0.00 per share	72.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEXO HEXO	-C$273.18M	-C$3.41	N/A	N/A		-220.13%	-106.39%	-14.96%	N/A
MPH Medicure	-C$2.03M	-C$0.65	N/A	N/A	N/A	-21.74%	-44.51%	-5.63%	N/A
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	N/A
VM Voyageur Pharmaceuticals	-C$1.66M	-C$0.02	N/A	N/A	N/A	-8,033.93%	-403.29%	-30.77%	N/A

Latest MPH, HEXO, VM, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEXO HEXO	N/A	N/A	N/A	N/A	N/A
MPH Medicure	N/A	2.24%	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
VM Voyageur Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEXO HEXO	125.99	0.41	0.40
MPH Medicure	6.34	1.04	1.29
VIR Vir Biotechnology	N/A	6.04	6.04
VM Voyageur Pharmaceuticals	9.80	0.23	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HEXO HEXO	7.57%
MPH Medicure	4.85%
VIR Vir Biotechnology	65.32%
VM Voyageur Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
HEXO HEXO	3.03%
MPH Medicure	26.68%
VIR Vir Biotechnology	2.90%
VM Voyageur Pharmaceuticals	10.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HEXO HEXO	690	44.00 million	N/A	Not Optionable
MPH Medicure	N/A	10.44 million	N/A	Not Optionable
VIR Vir Biotechnology	580	169.22 million	164.31 million	Optionable
VM Voyageur Pharmaceuticals	N/A	226.34 million	N/A	Not Optionable

MPH, HEXO, VM, and VIR Headlines

Recent News About These Companies

Voyageur Pharmaceuticals aims for Q2 2027 FDA approval to lead medical imaging supply chain

August 5, 2026 | bnnbloomberg.caB

VM:CA Voyageur Pharmaceuticals Ltd.

July 24, 2026 | seekingalpha.com

Voyageur Pharmaceuticals Ltd.: Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker

July 17, 2026 | finanznachrichten.de

Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption

June 5, 2026 | finance.yahoo.com

Voyageur Announces Non-Brokered Life Offering

March 25, 2026 | mining.com

Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial With Alberta Innovates Grant; Announces ...

March 4, 2026 | finance.yahoo.com

Voyageur Pharmaceuticals Gains Full Control of Iodine Technology, Names New Director of Chemistry

January 14, 2026 | theglobeandmail.com

Voyageur Pharmaceuticals Strengthens Board for U.S. Expansion

November 7, 2025 | tipranks.com

Voyageur Pharmaceuticals Expands Board with Wall Street Experts for U.S. Market Growth

October 23, 2025 | tipranks.com

Voyageur Pharmaceuticals Launches First Commercial Shipments of Barium Contrast Products in Canada

August 21, 2025 | msn.com

Voyageur Pharmaceuticals Gains $1.69 Million from Warrant Exercise

August 20, 2025 | msn.com

Voyageur Pharmaceuticals Advances Frances Creek Project with VAST Engagement

August 18, 2025 | msn.com

Voyageur Pharmaceuticals Ltd. (CVE:VM) Director Eugene Leonard Fritzel Acquires 32,250 Shares

July 1, 2025 | insidertrades.com

Voyageur Pharmaceuticals Launches First Commercial Sale of Barium Contrast Agents

June 4, 2025 | msn.com

Voyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study Results

April 24, 2025 | finance.yahoo.com

Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch

April 1, 2025 | finance.yahoo.com

Voyageur Pharmaceuticals Ltd.: Voyageur Clarifies Terms of Previously Announced Agreement

March 3, 2025 | finanznachrichten.de

Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes

February 18, 2025 | finance.yahoo.com

Voyageur Pharmaceuticals With CEO, Brent Willis | February 6th, 2025

February 6, 2025 | msn.com

Voyageur Receives $600K Grant From Alberta Innovates for Product Development

February 6, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MPH, HEXO, VM, and VIR Company Descriptions

HEXO TSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.

Medicure CVE:MPH

C$1.36 0.00 (0.00%)

As of 12:13 PM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Vir Biotechnology NASDAQ:VIR

$9.18 +0.18 (+1.94%)

As of 03:05 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Voyageur Pharmaceuticals CVE:VM

C$0.16 -0.01 (-2.94%)

As of 01:12 PM Eastern

Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. was founded in 2017 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MPH, HEXO, VM, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MPH, HEXO, VM, and VIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MPH, HEXO, VM, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MPH, HEXO, VM, and VIR Company Descriptions

HEXO TSE:HEXO

Medicure CVE:MPH

Vir Biotechnology NASDAQ:VIR

Voyageur Pharmaceuticals CVE:VM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MPH, HEXO, VM, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MPH, HEXO, VM, and VIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MPH, HEXO, VM, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MPH, HEXO, VM, and VIR Company Descriptions

HEXO TSE:HEXO

Medicure CVE:MPH

Vir Biotechnology NASDAQ:VIR

Voyageur Pharmaceuticals CVE:VM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools